<?xml version='1.0' encoding='utf-8'?>
<document id="29117990"><sentence text="Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin."><entity charOffset="181-192" id="DDI-PubMed.29117990.s1.e0" text="Midostaurin" /></sentence><sentence text="Midostaurin (PKC412) is being investigated for the treatment of acute myeloid leukemia (AML) and advanced systemic mastocytosis (advSM)"><entity charOffset="0-11" id="DDI-PubMed.29117990.s2.e0" text="Midostaurin" /><entity charOffset="13-19" id="DDI-PubMed.29117990.s2.e1" text="PKC412" /><pair ddi="false" e1="DDI-PubMed.29117990.s2.e0" e2="DDI-PubMed.29117990.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29117990.s2.e0" e2="DDI-PubMed.29117990.s2.e1" /></sentence><sentence text=" It is extensively metabolized by CYP3A4 to form two major active metabolites, CGP52421 and CGP62221" /><sentence text=" In vitro and clinical drug-drug interaction (DDI) studies indicated that midostaurin and its metabolites are substrates, reversible and time-dependent inhibitors, and inducers of CYP3A4"><entity charOffset="74-85" id="DDI-PubMed.29117990.s4.e0" text="midostaurin" /></sentence><sentence text=" A simultaneous pharmacokinetic model of parent and active metabolites was initially developed by incorporating data from in vitro, preclinical, and clinical pharmacokinetic studies in healthy volunteers and in patients with AML or advSM" /><sentence text=" The model reasonably predicted changes in midostaurin exposure after single-dose administration with ketoconazole (a 5"><entity charOffset="43-54" id="DDI-PubMed.29117990.s6.e0" text="midostaurin" /><entity charOffset="102-114" id="DDI-PubMed.29117990.s6.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29117990.s6.e0" e2="DDI-PubMed.29117990.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29117990.s6.e0" e2="DDI-PubMed.29117990.s6.e1" /></sentence><sentence text="8-fold predicted versus 6" /><sentence text="1-fold observed increase) and rifampicin (90% predicted versus 94% observed reduction) as well as changes in midazolam exposure (1"><entity charOffset="30-40" id="DDI-PubMed.29117990.s8.e0" text="rifampicin" /></sentence><sentence text="0 predicted versus 1" /><sentence text="2 observed ratio) after daily dosing of midostaurin for 4 days"><entity charOffset="40-51" id="DDI-PubMed.29117990.s10.e0" text="midostaurin" /></sentence><sentence text=" The qualified model was then applied to predict the DDI effect with other CYP3A4 inhibitors or inducers and the DDI potential with midazolam under steady-state conditions"><entity charOffset="132-141" id="DDI-PubMed.29117990.s11.e0" text="midazolam" /></sentence><sentence text=" The simulated midazolam area under the curve ratio of 0"><entity charOffset="15-24" id="DDI-PubMed.29117990.s12.e0" text="midazolam" /></sentence><sentence text="54 and an accompanying observed 1" /><sentence text="9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM"><entity charOffset="52-73" id="DDI-PubMed.29117990.s14.e0" text="4β-hydroxycholesterol" /><entity charOffset="123-134" id="DDI-PubMed.29117990.s14.e1" text="midostaurin" /><pair ddi="false" e1="DDI-PubMed.29117990.s14.e0" e2="DDI-PubMed.29117990.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29117990.s14.e0" e2="DDI-PubMed.29117990.s14.e1" /></sentence><sentence text=" In conclusion, a simultaneous parent-and-active-metabolite modeling approach allowed predictions under steady-state conditions that were not possible to achieve in healthy subjects" /><sentence text=" Furthermore, endogenous biomarker data enabled evaluation of the net effect of midostaurin and its metabolites on CYP3A4 activity at steady state and increased confidence in DDI predictions"><entity charOffset="80-91" id="DDI-PubMed.29117990.s16.e0" text="midostaurin" /></sentence><sentence text="" /></document>